In addition, c-MET is overexpressed in various cancers, including lymphoma, melanoma, glioma, breast cancer, pancreatic cancer, colorectal cancer, and ovarian cancer [36,37,38,39,40,41]. This evidence concerns the gene MET and ovarian carcinoma.